HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs may improve breast cancer survival, observational studies suggest

Louis Nervegna · Dec 22, 2025 · ♥ 7 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Cancer
AI summary & key facts

Three large observational studies suggest GLP-1 drugs may improve survival in some breast cancer patients, including DCIS and HR-positive disease.

GLP-1 agonist drugs may improve survival in breast cancer.

(Lots of evidence in animal models shows calorie restriction slows cancer growth.)

#glp1HD #breastcancerHD #caloriecrestrictionHD

Research cited

Shared from Medscape · original post

A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that GLP-1 receptor agonists may improve outcomes in some women with breast cancer.

Two studies reported an overall survival benefit of GLP-1 use in certain patients with breast cancer, including those with ductal carcinoma in situ (DCIS) and invasive hormone receptor (HR)-positive nonmetastatic disease, and a third found improvements in a range of toxicities among patients receiving chemotherapy. Beyond Weight Loss: GLP-1s Show Promise in Breast Cancer (Medscape)

No photo description available.
← newer: Dairy fat and dementia study flagged as imperfect and needinolder: Omega-6 activates PPAR-gamma, the same pathway as glitazone →